• Editas Medicine (NASDAQ:EDIT) announced Tuesday it would seek a global partner or an out-licensing deal as it reviews the path to further advance its gene editing candidate reni-cel amid plans to reduce expenditure in 2025.
• Formerly known as EDIT-301, renizgamglogene autogedtemcel

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.